These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 39073639)
1. Marine sponge-derived alkaloid inhibits the PI3K/AKT/mTOR signaling pathway against diffuse large B-cell lymphoma. Liu J; Chang YT; Kou YY; Zhang PP; Dong QL; Guo RY; Liu LY; Lin HW; Yang F Med Oncol; 2024 Jul; 41(9):212. PubMed ID: 39073639 [TBL] [Abstract][Full Text] [Related]
2. Marine Sponge-Derived Alkaloid Induces Mitochondrial Dysfunction and Inhibits the PI3K/AKT/mTOR Signaling Pathway against Burkitt's Lymphoma. Zhao HM; He J; Chang YT; Liu LY; Sun F; Lin HW; Yang F J Nat Prod; 2023 Jan; 86(1):45-51. PubMed ID: 36524671 [TBL] [Abstract][Full Text] [Related]
3. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab. Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313 [TBL] [Abstract][Full Text] [Related]
4. Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma. Jin Z; Qing K; Ouyang Y; Liu Z; Wang W; Li X; Xu Z; Li J J Exp Clin Cancer Res; 2016 Mar; 35():52. PubMed ID: 27009084 [TBL] [Abstract][Full Text] [Related]
5. Anti-DLBCL efficacy of DCZ0825 in vitro and in vivo: involvement of the PI3K‒AKT‒mTOR/JNK pathway. Hu K; Li B; Ma R; Yi H; Xu Z; Peng Y; Yu D; Wu H; Cheng T; Lu Y; Zhang Y; Wei R; Yang G; Wu X; Zhu W; Shi J Acta Biochim Biophys Sin (Shanghai); 2021 Apr; 53(5):575-583. PubMed ID: 33821934 [TBL] [Abstract][Full Text] [Related]
7. Fat mass and obesity-associated protein (FTO)-induced upregulation of flotillin-2 (FLOT2) contributes to cancer aggressiveness in diffuse large B-cell lymphoma (DLBCL) via activating the PI3K/Akt/mTOR signal pathway. Zhang Y; Chen Y; Guo Q; Zhang Y; Liu A Arch Biochem Biophys; 2024 Aug; 758():110072. PubMed ID: 38914215 [TBL] [Abstract][Full Text] [Related]
8. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma. Chen J; Ge X; Zhang W; Ding P; Du Y; Wang Q; Li L; Fang L; Sun Y; Zhang P; Zhou Y; Zhang L; Lv X; Li L; Zhang X; Zhang Q; Xue K; Gu H; Lei Q; Wong J; Hu W Theranostics; 2020; 10(7):3151-3163. PubMed ID: 32194860 [TBL] [Abstract][Full Text] [Related]
9. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma. Petrich AM; Leshchenko V; Kuo PY; Xia B; Thirukonda VK; Ulahannan N; Gordon S; Fazzari MJ; Ye BH; Sparano JA; Parekh S Clin Cancer Res; 2012 May; 18(9):2534-44. PubMed ID: 22338016 [TBL] [Abstract][Full Text] [Related]
10. Polyphyllin I Promoted Melanoma Cells Autophagy and Apoptosis via PI3K/Akt/mTOR Signaling Pathway. Long J; Pi X Biomed Res Int; 2020; 2020():5149417. PubMed ID: 32733943 [TBL] [Abstract][Full Text] [Related]
11. Chidamide and orelabrutinib synergistically induce cell cycle arrest and apoptosis in diffuse large B-cell lymphoma by regulating the PI3K/AKT/mTOR pathway. Wu C; Chen S; Wu Z; Xue J; Zhang W; Wang S; Xindong Zhao ; Wu S J Cancer Res Clin Oncol; 2024 Feb; 150(2):98. PubMed ID: 38381215 [TBL] [Abstract][Full Text] [Related]
12. DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway. Sun X; Li B; Xie B; Xu Z; Chang G; Tao Y; Zhang Y; Chang S; Wang Y; Yu D; Xie Y; Li T; Wang H; Chen G; Hu L; Hou J; Zhang Y; Xiao W; Gao L; Shi J; Zhu W Cell Death Dis; 2017 Oct; 8(10):e3111. PubMed ID: 29022919 [TBL] [Abstract][Full Text] [Related]
13. PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas. Chen D; Mao C; Zhou Y; Su Y; Liu S; Qi WQ Int J Oncol; 2016 Jan; 48(1):253-60. PubMed ID: 26549638 [TBL] [Abstract][Full Text] [Related]
14. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy. Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503 [TBL] [Abstract][Full Text] [Related]
15. DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway. Chang S; Li B; Xie Y; Wang Y; Xu Z; Jin S; Yu D; Wang H; Lu Y; Zhang Y; Ma R; Huang C; Lai W; Wu X; Zhu W; Shi J Neoplasia; 2022 Jan; 24(1):50-61. PubMed ID: 34890905 [TBL] [Abstract][Full Text] [Related]
16. Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma. Ezell SA; Wang S; Bihani T; Lai Z; Grosskurth SE; Tepsuporn S; Davies BR; Huszar D; Byth KF Oncotarget; 2016 Feb; 7(8):9163-74. PubMed ID: 26824321 [TBL] [Abstract][Full Text] [Related]
17. Chloroform extract from Sophora Tonkinensis Gagnep. inhibit proliferation, migration, invasion and promote apoptosis of nasopharyngeal carcinoma cells by silencing the PI3K/AKT/mTOR signaling pathway. ShuoWang ; Song Z; Gong X; Ou C; Zhang W; Wang J; Yao C; Qin S; Yan B; Li Q; Wei K; Hou X; Zhou X; Miao J J Ethnopharmacol; 2021 May; 271():113879. PubMed ID: 33524509 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of Prostate Cancer DU-145 Cells Proliferation by Li X; Tang Y; Yu F; Sun Y; Huang F; Chen Y; Yang Z; Ding G Mar Drugs; 2018 Sep; 16(9):. PubMed ID: 30208576 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance. Majchrzak A; Witkowska M; Smolewski P Molecules; 2014 Sep; 19(9):14304-15. PubMed ID: 25215588 [TBL] [Abstract][Full Text] [Related]
20. Annexin A5 inhibits diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling. Wang J; Zhang Y; Liu X; Ma J; Liu P; Hu C; Zhang G Oncol Rep; 2014 Dec; 32(6):2557-63. PubMed ID: 25323007 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]